WO2014032541A1 - 一种治疗艾滋病的中药制剂及相应的制备方法 - Google Patents
一种治疗艾滋病的中药制剂及相应的制备方法 Download PDFInfo
- Publication number
- WO2014032541A1 WO2014032541A1 PCT/CN2013/082076 CN2013082076W WO2014032541A1 WO 2014032541 A1 WO2014032541 A1 WO 2014032541A1 CN 2013082076 W CN2013082076 W CN 2013082076W WO 2014032541 A1 WO2014032541 A1 WO 2014032541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- preparation
- powder
- chinese medicine
- medicinal
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 42
- 208000030507 AIDS Diseases 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 31
- 235000006533 astragalus Nutrition 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 241000756042 Polygonatum Species 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 5
- 241000576429 Forsythia suspensa Species 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims description 65
- 239000000463 material Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 17
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000002002 slurry Substances 0.000 claims description 14
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 12
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 229940010454 licorice Drugs 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000428 dust Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 241000037831 Polygonatum sibiricum Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 244000046101 Sophora japonica Species 0.000 claims 5
- 235000010586 Sophora japonica Nutrition 0.000 claims 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims 3
- 235000017443 Hedysarum boreale Nutrition 0.000 claims 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims 2
- 244000184734 Pyrus japonica Species 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000020985 whole grains Nutrition 0.000 claims 1
- 241001061264 Astragalus Species 0.000 abstract description 18
- 210000004233 talus Anatomy 0.000 abstract description 18
- 241000405414 Rehmannia Species 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 3
- 241000050051 Chelone glabra Species 0.000 abstract 2
- 241000233866 Fungi Species 0.000 abstract 2
- 240000001307 Myosotis scorpioides Species 0.000 abstract 2
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 2
- 241000219784 Sophora Species 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- 241000125175 Angelica Species 0.000 description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 description 15
- 241000202807 Glycyrrhiza Species 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 241000555712 Forsythia Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 239000002398 materia medica Substances 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 210000004970 cd4 cell Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000190633 Cordyceps Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 244000227633 Ocotea pretiosa Species 0.000 description 3
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 3
- 241000207929 Scutellaria Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 235000017784 Mespilus germanica Nutrition 0.000 description 2
- 244000182216 Mimusops elengi Species 0.000 description 2
- 235000000560 Mimusops elengi Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000973598 Oxyjulis californica Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 235000007837 Vangueria infausta Nutrition 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000009530 yishen Substances 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 101710150766 Sialic acid-binding lectin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000026058 directional locomotion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine preparation for treating AIDS and a corresponding preparation method.
- an embodiment of the present invention provides a traditional Chinese medicine preparation for treating AIDS, which is a preparation prepared from the following weight ratio raw materials:
- the traditional Chinese medicine preparation component is at least one of all the compounds, biologically active ingredients, various molecular clusters and derivatives, and all chemical compounds extracted from the respective raw materials.
- the present invention provides a preparation method of a traditional Chinese medicine preparation for treating AIDS, comprising: taking a medicinal material of Cordyceps sinensis, sassafras, forsythia, and citric acid according to the weight ratio of components, and pulverizing to 80 mesh. 80 mesh sieve, sterilized the powder after 80 mesh sieve, and set aside;
- the sterilized powder, the extract powder and the medicinal auxiliary material are mixed by a tank mixer for 50 minutes, and then granulated into a 80-mesh sieve, and the medicated powder after sieving is sterilized.
- the pharmaceutical excipient is at least one of maltodextrin, pregelatinized starch and lactose;
- the above mixed and sterilized powder is prepared into any one of capsules, tablets, syrups, oral solutions or granules.
- the method further comprises:
- the step of performing dust removal treatment on the medicinal material includes:
- the package of Cordyceps sinensis, sassafras, forsythia, and citric acid is further packaged before being crushed.
- the temperature is controlled at 60 ⁇ 5 ° C, and dried to a moisture content of 3 to 8%.
- the sterilization process is specifically:
- the sterilizing treatment is carried out by at least one of a cobalt 60 sterilization method, an ultraviolet sterilization method, and an ozone sterilization method.
- the step of drying and concentrating the filtrate into a relative density of 1.2 to 1.25 is specifically as follows:
- the filtrate was dried by steam drying at a drying temperature of 90 ⁇ 5 °C.
- the step of preparing the mixed and sterilized powder into tablets is specifically: adding 1400 parts of hydroxypropyl fluorenylcellulose HPMC and 400 parts of polyethylene glycol PEG to 20,000 parts of purified water at 60 ° C, respectively. Stirring, fully swelling, and then adding 20,000 parts of 95% ethanol to prepare a film-coated white film slurry. This process is prepared 24 hours before coating, adding 2,000 parts of titanium dioxide and 1000 parts of talc before coating. After mixing, the hook is passed through the colloid mill;
- the present invention treats AIDS through the combination of heat-clearing and detoxifying (anti-microbial pathogens) and strengthening the body's immune function (enhancing human immune function), and draws on the results of modern pharmacological research, screening
- the traditional Chinese medicine which meets the rule of the present invention produces a traditional Chinese medicine preparation product having obvious therapeutic effects.
- the invention has obvious curative effect in clinical application, and has high application and promotion value, and has significant effects on improving clinical symptoms of AIDS patients and improving the quality of life of patients. 3.
- the raw material of the present invention is easy to obtain, has low cost, has no obvious side effects, and has high safety.
- the traditional Chinese medicine preparation component is at least one of all compounds, biologically active components, various molecular clusters and derivatives, and all chemical compositions extracted from the respective raw materials.
- the invention also discloses a preparation method of the above traditional Chinese medicine preparation, comprising:
- Step 1 According to the weight ratio of each component in the above-mentioned Embodiments 1 to 6, respectively, the medicinal materials of Cordyceps sinensis, sassafras, forsythia, and citric acid are respectively pulverized to 80 mesh and passed through a mesh of 80 mesh, and 80 meshes are passed. The sifted powder is sterilized and used;
- the flowers of scutellaria, forsythia, and sage can be dehydrated by a centrifuge, and the temperature is controlled to be dried at 60 ⁇ 5 ° C, and dried to a moisture content of 3 to 8%.
- the sterilization treatment may be performed by at least one of a cobalt 60 sterilization method, an ultraviolet sterilization method, and an ozone sterilization method.
- Step 2 taking the weight ratio of each component in the above-mentioned Embodiments 1 to 6 respectively, taking Astragalus, Polygonatum, Licorice, Astragalus, Rehmannia glutinosa and Angelica sinensis, and further including picking the six medicinal materials in this step, Removing impurities and non-medicinal parts from the medicinal material and filling the proportion;
- Step 3 Perform dust removal treatment on the medicinal materials in step two; the specific ones may be:
- the medicinal materials selected in the second step are vibrated by the electric vibrating screen for 10 minutes, and the dust mixed in the medicinal materials is removed after the vibration; or
- Step 4 After the dust removal treatment, Astragalus, Polygonatum, Licorice, Astragalus, Angelica and Rehmannia glutinosa, directly add water to cook twice, for the first time, add water for 10 hours according to the original amount of the original medicine for 2 hours, the second time, Decoction for 8 hours with water of 8 times the original medicinal material, filtered, and the filtrate was combined;
- Step 5 The filtrate is dried and concentrated to a concentration of 1.2 ⁇ 1.25, specifically: drying the filtrate by vacuum spray drying at a drying temperature of 30 ⁇ 50 ° C; or
- the filtrate is dried by a steam drying method with a drying temperature of 90 ⁇ 5 ° C to obtain an extract having a relative density of 1.2 to 1.25;
- Step 6 The powder obtained in the above step 1 and the extract powder obtained in the step 5, and the medicinal auxiliary material are mixed by a tank mixer for 50 minutes, and then granulated through a 80 mesh sieve, and sieved and mixed. The powder is sterilized.
- the pharmaceutical excipient is at least one of maltodextrin, pregelatinized starch and lactose.
- the sterilization treatment is carried out by at least one of a cobalt 60 sterilization method, an ultraviolet sterilization method, and an ozone sterilization method.
- the mixed and sterilized powder is prepared into any one of a capsule, a tablet, a syrup, an oral solution or a granule powder.
- step 7 the steps of preparing the capsule in step 7 are as follows:
- the mixed and sterilized powder is mixed by a tank mixer for 50 minutes, thoroughly mixed, and uniformly mixed. Then, in a clean workshop, a plastic bottle is produced through a plastic bottle filling production line, and the content of each capsule is 400 mg. And maintain a moisture content of 4 ⁇ 8%. Third, the tablet production process steps
- step 7 The steps for making tablets in step 7 are as follows:
- the mixed and sterilized powder is obtained in step 6.
- the tablet production line is tablet-formed, wherein the preparation of the tablet is 25 parts by weight of maltodextrin, 25 parts of pregelatinized starch and lactose. Share.
- the powder and the medicinal auxiliary material are mixed by a tank mixer for 50 minutes, then dried in a stainless steel pan, dried at a temperature of 90 ° C, dried and pulverized to 80 mesh by a pulverizer, and passed through 80 mesh. The granules are sieved.
- the pressed substrate into the high-efficiency coating machine, start the various systems of the coating equipment according to the conventional preparation process, and adjust the parameters such as the spray speed, air intake, inlet air temperature, pot speed, exhaust air volume, etc.
- the white film slurry is sprayed onto the bed, and after 2 to 3 hours, the surface is smooth and delicate; then the prepared color film slurry is sprayed onto the bed, and after 2 to 3 hours, the surface is fine and the color is uniform.
- auxiliary materials are processed according to the active characteristics of the drugs and auxiliary materials, such as milling, water extraction and mixing.
- the net weight of each tablet is 500 mg, and the water content is kept at 4 to 8%.
- the raw materials for each component used in the present invention can be found in the Pharmacopoeia of the People's Republic of China (2010 edition) and the quality assessment of Chinese herbal medicines and medicinal excipients formulated by relevant departments of the provinces, municipalities, districts, health, food and food supervision and management. Standard record.
- the pharmacopoeia records and pharmacological studies of the ten medicinal materials in the prescription of the present invention are as follows:
- MTT colorimetric assay was used to detect the toxicity of compounds on various cells. The compound was assayed for anti-HIV-1 activity in vitro by means of syncytium formation counting, p24 antigen capture ELISA and RT-PCR.
- the extract of compound K3 has good anti-HIV-1 activity in vitro, and it can inhibit various viral strains (HIV-1IIIB), drug resistant strains (HIV-1 74v) and clinical isolates (HIV-1KM018).
- the replication of the virus strain, and its mechanism of action is multi-target, not only can inhibit the entry of the virus, but also inhibit the activity of HIV-1 reverse transcriptase.
- Lectin is a multifunctional mannose/sialic acid-binding lectin purified from the traditional Chinese herbal medicine Liliaceae, in addition to hemagglutination activity and lymphocyte mitogenic activity.
- Lectin anti-human herpes simplex virus activity and anti-hepatitis B virus activity showed its special biological activity; the study also found that lectin can effectively prevent human immunodeficiency virus (HIV-1/2) from infecting normal cells. (Source: “The Tenth China Biophysics Academic Conference Abstracts” 2006)
- the immunosuppressive mouse model was established by cyclophosphamide modeling, and the effects of Rehmannia glutinosa polysaccharide on phagocytosis, hemolysin formation, hemolytic plaque formation and lymphocyte transformation of peritoneal macrophages were observed.
- the dose of Rehmannia glutinosa polysaccharide can increase the percentage of phagocytosis and phagocytic index significantly; it can significantly promote the formation of hemolysin and hemolytic plaque, and promote the transformation of lymphocytes.
- Forsythia is a commonly used traditional Chinese medicine for clearing heat, which has inhibitory effects on various viruses such as syncytial virus, herpes simplex virus and influenza virus. (Source: China Medical Herald, 2010, Issue 02, “Research Progress of Anti-Virus for Anti-Vibration”)
- Cordyceps not only has dilated bronchus, regulates heartbeat, sedative hypnosis, androgen-like effects, but also has anti-cancer, hypoglycemic, anti-inflammatory and immunomodulatory effects. Especially in recent years, the anti-inflammatory and immunomodulatory effects of Cordyceps have become a hot research topic. Many experts and scholars have conducted in-depth research on the anti-inflammatory and immunomodulatory effects of Cordyceps, and found that Cordyceps has enhanced mononuclear-macrophage phagocytosis and stimulates T.
- Lymphocyte proliferation enhances the proliferation of lymphocytes induced by ConA and PHA, antagonizes the effects of immunosuppressive agents such as prednisone, and can affect many cytokines.
- immunosuppressive agents such as prednisone
- Angelica sinensis polysaccharide is one of the main components of Angelica.
- AP Angelica sinensis polysaccharide
- ⁇ macrophages
- Angelica can promote macrophage secretion of cytokines and enhance immune function.
- Angelica polysaccharide (AP) combined with tumor vaccine can significantly enhance the macrophage-mediated cytotoxicity of tumor-bearing mice, and improve the anti-tumor effect of tumor vaccine.
- AP can increase the blood calcium content of mice, thus supplementing the body's need for calcium, protecting immune cells, and enhancing the phagocytic function of macrophages.
- AP can enhance the expression of interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6) and interferon gamma (INF- ⁇ ), the process of which is first activated by non-specific immunity.
- IL-2 interleukin-2
- IL-4 interleukin-4
- IL-6 interleukin-6
- IFN- ⁇ interferon gamma
- Citric acid also known as sodium citrate, can form an insoluble complex with calcium ions in the blood. Calcium is one of the substances required in the blood coagulation process, and the blood is reduced by calcium ions. Blood coagulation is blocked. Since citric acid is weakly alkaline, it can regulate the pH of the human body in moderate use, and theoretically can inhibit the formation of blood cell syncytia to a certain extent.
- Citric acid is not used as a co-modulator in traditional Chinese medicine, and can be used in combination with Angelica Huoxue (anti-coagulation, inhibition of the formation of infected blood cell syncytia and reduction of CD4 cell apoptosis).
- the amount of each medicinal herb is also compatible according to the principle of Junchen.
- the present invention treats AIDS through the combination of heat-clearing and detoxifying (anti-microbial pathogens) and strengthening the body's immune function (enhancing human immune function), and draws on the results of modern pharmacological research, screening
- the traditional Chinese medicine which meets the rule of the present invention produces a traditional Chinese medicine preparation product having obvious therapeutic effects.
- the principles of the group are as follows: Qingrejiedu medicinal materials: Astragalus, Forsythia, and medlar; Fuzheng medicinal materials: Astragalus, Polygonatum, Rehmannia glutinosa, Angelica, Cordyceps sinensis, Licorice.
- the raw materials of the invention are easy to obtain, convenient to take, low in cost, no obvious side effects, and high in safety.
- the clinical effect is obvious, and the application promotion value is high. It is effective for improving the clinical symptoms of AIDS and improving the quality of life of patients.
- the preparation prepared by the invention is in the form of a prescription for traditional Chinese medicine. Since 2002, it has been widely used in volunteers of AIDS patients in Yunnan and Henan, and has shown many positive effects. After improvement, the use of capsules: AIDS patients and HIV-infected patients taking 12 capsules a day can significantly improve symptoms, improve liver function, and no side effects of Western medicine antiviral drugs. After taking it, the quality of life improved, the appetite improved, the quality of life improved significantly, the survival period prolonged, and the normal life and work ability gradually returned.
- the present invention uses a capsule preparation to treat preliminary clinical trials of HIV-infected and HIV-infected persons:
- peripheral blood CD4 cells are equal to or lower than 400 / ml, third, stop antiretroviral western medicine during medication Treatment and other antiviral medications, improve immune function medications.
- Each patient's treatment time was 12 months, and 12 capsules of the present invention were taken daily.
- CD4 and patient symptom improvement before and after treatment were used as self-control data as efficacy indicators.
- the efficacy criteria for combating HIV-1 are not included in this treatment observation due to the limitations of funds and conditions.
- AIDS is caused by HIV-1 infection. Due to the destruction of HIV, CD4 T lymphocytes are destroyed or the CD4 cell population is induced to apoptosis, and the CD4 cells of patients are gradually decreased. Therefore, only CD4 cells can be obtained only by inhibiting the virus. Preservation and recovery, but since this treatment did not include antiviral indicators in the observation system, there is no direct evidence for the anti-HIV efficacy of the prescription capsules of the present invention. Therefore, the prescription drugs of the present invention have been sent to Germany for virus experiments. The laboratory conducts a number of anti-virus-related tests for inhibiting HIV-1 activity, membrane fusion, and the like, and experiments are currently underway. The above is only the preferred embodiment of the present invention, and the scope of the present invention is not limited thereto, and thus equivalent variations are still within the scope of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗艾滋病的中药制剂及其制备方法。该中药制剂由黄芩、槐花、黄芪、当归、黄精、熟地黄、甘草、连翘、冬虫夏草、柠檬酸原料按比例制备而成,其制备方法为将将黄芪、黄精、甘草、黄芩、熟地黄加水煎煮干燥后得到的浸膏,与冬虫夏草、槐花、连翘、柠檬酸粉碎后的粉末混合,加入药用辅料,制成各种口服剂型。
Description
一种治疗艾滋病的中药制剂及相应的制备方法 本申请要求于 2012 年 8 月 27 日提交中国专利局、 申请号为 201210306769.7、 发明名称为 "一种治疗艾滋病的中药制剂及相应的制备方 法" 的中国专利申请的优先权, 上述专利的全部内容通过引用结合在本申请 中。 技术领域
本发明涉及中药技术领域,特别是涉及一种治疗艾滋病的中药制剂及相 应的制备方法。
背景技术
世界卫生组织 ( WHO )报告 2010年全世界存活 HIV携带者及艾滋病 患者共 3400万, 新感染 270万, 全年死亡 180万人。 每天有超过 7000人新 发感染, 全世界各地区均有流行, 但 97%以上在中、 低收入国家, 尤以非洲 为重。 专家估计, 全球流行重灾区可能会从非洲移向亚洲。 据中国疾病预防 控制中心估计, 截止至 2011年底, 我国存活 HIV携带者及艾滋病患者约 78 万人, 全年新发感染者 4.8万人, 死亡 2.8万人。 疫情已覆盖全国所有省、 自治区、 直辖市, 目前我国面临艾滋病发病和死亡的高峰期, 且已由吸毒、 暗娼等高危人群开始向一般人群扩散。
随着全球抗逆转录药物的普及, 艾滋病病毒对西药的耐药性问题也越来 越突出。 世界卫生组织艾滋病司司长戈特弗里德.希恩沙尔说: 截至 2011年 年底, 中低收入国家有 800万艾滋病病毒感染者接受抗逆转录药物治疗, 比 2003年增加了 20多倍, 药物覆盖范围扩大的后果之一是病毒开始出现耐药 性, 且价格昂贵, 许多患者无力承担。
而研究结果表明: 中药对改善艾滋病的症状体征疗效确切(如乏力、 腹 泻、 发热、 皮疹等); 可以明显改善患者的生存质量; 对提高和稳定患者的 免疫功能具有一定的作用。 因此从来源广泛、 毒副作用小、 价格低廉的中药 中寻找高效的抗 HIV药物已成为有关艾滋病研究的重要研究课题之一。 发明内容
本发明所要解决的技术问题在于, 提供一种治疗艾滋病的中药制剂, 该 中药制剂的在治疗艾滋病方面效果好、 安全可靠且价格便宜, 同时本发明还 提供了该中药制剂的相应制备方法。
为了解决上述技术问题, 一方面, 本发明的实施例提供了一种治疗艾滋 病的中药制剂, 是由下述重量配比的原料制成的制剂:
黄芩 60 ~ 90份, 槐花 60 ~ 90份, 黄芪 120 ~ 250份, 当归 120份 -250 份, 黄精 120 ~ 250份, 熟地黄 90 ~ 150份, 甘草 20 ~ 55份, 连翘 120 ~ 250 份, 冬虫夏草 25 ~ 60份, 柠檬酸 60 ~ 90份。
优选地, 所述中药制剂组分是各配比原料中提取的所有化合物、 生物活 性成分及各类分子簇及衍生物、 全化学合成物中至少一种。
另一方面, 本发明提供一种治疗艾滋病的中药制剂的制备方法, 包括: 按组分重量配比分别取冬虫夏草、 槐花、 连翘、 柠檬酸四味药料, 经粉 碎至 80目后过 80目筛, 对过 80目筛后的药粉进行灭菌处理, 备用;
按组份重量配比分别取黄芪、 黄精、 甘草、 黄芩、 当归和熟地黄, 加水 煎煮二次: 第一次按原药材的 10倍重量加水煎煮 2小时, 第二次按原药材 的 8倍量加水煎煮 2 小时, 滤过并合并滤液, 将滤液干燥浓缩成相对密度 1.2 ~ 1.25的浸膏, 经粉碎至 80目后过 80目筛获得浸膏粉体, 备用;
将上述灭菌后的药粉、 浸膏粉体及药用辅料采用槽混机进行混合 50分 钟后, 再对其进行整粒过 80 目筛, 对过筛混合后的药粉行灭菌处理, 所用 的药用辅料为麦芽糊精、 预胶化淀粉和乳糖中至少一种;
将上述混合且灭菌后的药粉制备成胶嚢、 片剂、 糖浆剂、 口服液或颗粒 散剂中的任一种。
优选地, 在按重量配比取黄芪、 当归、 黄精、 甘草、 黄芩、 熟地黄、 槐 花、 连翘、 冬虫夏草之后, 进一步包括:
对所述药材进行去尘处理的步骤, 包括:
用电动振筛进行振动 10分钟, 经振动后将混杂在药材中的粉尘除去, 或者
用饮用流动水清洗至少二次。
优选地, 对冬虫夏草、 槐花、 连翘、 柠檬酸四味药料粉碎之前进一步包
括:
将槐花、 连翘、冬虫夏草药材用离心机进行脱水后,控制温度在 60±5°C 进行干燥, 干燥至含水率 3 ~ 8%。
优选地, 所述灭菌处理具体为:
用钴 60灭菌方法、 紫外线灭菌方法、 臭氧灭菌方法中至少一种进行灭 菌处理。
优选地, 所述将滤液干燥浓缩成相对密度 1.2 ~ 1.25的浸膏的步骤具体 为:
采用干燥温度为 30 ~ 50°C的真空喷雾干燥方式对滤液进行干燥处理;或 者
采用干燥温度为 90±5°C的蒸汽干燥方式对滤液进行干燥处理。
优选地, 将上述混合且灭菌后的药粉制备成片剂的步骤具体为: 将羟丙基曱基纤维素 HPMC1400份和聚乙二醇 PEG400份先后加入到 20000份 60 °C纯化水中, 边加边搅拌, 充分溶胀后再加入 20000份 95 %的 乙醇配制得到包薄膜衣的白膜浆, 此过程在包衣前 24小时制备, 包衣前加 入 2 000份钛白粉和 1000份滑石粉, 搅拌均勾后过胶体磨;
称取纯化水 10500份, 将搅拌器伸入液面下 2/3处, 启动搅拌器, 使液 面形成漩涡, 将红色粉末的包衣剂 GMI 2 000份以平稳的速度不断撒在漩涡 液面上, 再持续搅拌 45分钟至包衣剂完全溶散配制得包薄膜衣的色膜浆; 将所述混合且灭菌后的药粉压制成基片, 将所述基片放入高效包衣机 内, 采用常规的制剂工艺, 将配制好的白膜浆喷向片床, 经 2 ~ 3 小时后, 再将配制好的色膜浆喷向片床, 经 2 ~ 3小时后, 片面光滑细腻即得。
实施本发明实施例所提供的一种, 具有如下有益效果:
1、本发明在中医理论的指导下,其是通过清热解毒(抗微生物病原体)、 扶正祛湿(增强人体免疫机能)相结合的原则来治疗艾滋病, 同时借鉴了现 代药理学研究的成果, 筛选出符合本发明治则的中药, 制出具有明显治疗效 果的中药制剂产品。
2、 本发明在临床应用中疗效明显, 应用推广价值高, 对于改善艾滋病 人临床症状, 提高病人的生存生活质量效果显著。
3、 本发明的原料容易取得, 成本低, 未见明显的副作用, 安全性高。
具体实施方式
下面对本发明的优选实施例进行描述。
在下述实施例一至实施例六中,本发明的治疗艾滋病的中药制剂由下述 原料按其重量比制备而成:
其中, 所述中药制剂组分是各配比原料中提取的所有化合物、 生物活性 成分及各类分子簇及衍生物、 全化学合成物中至少一种。
本发明还公开了上述中药制剂的制备方法, 包括:
一、 原料生产工艺步骤
步骤一、 按上述实施例一至实施例六中各组分重量配比分别取冬虫夏 草、 槐花、 连翘、 柠檬酸四味药料, 经粉碎至 80 目后过 80 目筛, 对过 80 目筛后的药粉进行灭菌处理, 备用;
其中, 在粉碎之前, 可以将槐花、 连翘、 冬虫夏草药材用离心机进行脱 水后, 控制温度在 60±5°C进行干燥, 干燥至含水率 3 ~ 8%。
其中, 灭菌处理可以是用钴 60灭菌方法、 紫外线灭菌方法、 臭氧灭菌 方法中至少一种进行灭菌处理。
步骤二、 按上述实施例一至实施例六中各组分的重量比, 分别取黄芪、 黄精、 甘草、 黄芩、 熟地黄和当归, 在这一步骤中进一步可以包括对该六种 药材进行拣选, 去除药材中的杂质和非药用部分并补齐配比量;
步骤三. 对步骤二中的药材进行除尘处理; 具体可以为:
对步骤二中拣选合格的药材用电动振筛进行振动 10分钟, 经振动后将 混杂在药材中的粉尘除去; 或者
用饮用流动水对上述药材清洗至少二次。
步骤四, 将经除尘处理后的黄芪、 黄精、 甘草、 黄芩、 当归和熟地黄, 直接加水煎煮二次, 第一次, 按原药材的 10倍量加水煎煮 2小时, 第二次, 按原药材的 8倍量加水煎煮 2小时, 滤过, 合并滤液;
步骤五, 滤液干燥浓缩成相对密度 1.2 ~ 1.25的浸膏, 具体地: 采用干燥温度为 30 ~ 50°C的真空喷雾干燥方式对滤液进行干燥处理;或 者
采用干燥温度为 90±5 °C的蒸汽干燥方式对滤液进行干燥处理获得相对 密度为 1.2〜1.25的浸膏;
并将上述浸膏粉碎后过 80目筛获得浸膏粉体, 备用;
步骤六, 将上述步骤一获得的药粉和步骤五获得的浸膏粉体, 以及药用 辅料采用槽混机进行混合 50分钟后, 再对其进行整粒过 80目筛, 过筛混合 后的药粉进行灭菌处理。 其中, 所述药用辅料是麦芽糊精、 预胶化淀粉和乳 糖中至少一种。
其中, 灭菌处理为用钴 60灭菌方法、 紫外线灭菌方法、 臭氧灭菌方法 中至少一种进行灭菌处理。
步骤七, 将上述混合且灭菌后的药粉制备成胶嚢、 片剂、 糖浆剂、 口服 液或颗粒散剂中的任一种。
二、 胶嚢剂生产工艺步骤
进一步地, 其中步骤七中制成胶嚢剂的步骤如下:
将混合且灭菌后的药粉, 采用槽混机进行混合 50分钟充分搅拌、 混合 匀均后, 在洁净车间通过胶嚢灌装生产线制成胶嚢, 每粒胶嚢内容物净装量 为 400mg, 并保持含水率 4 ~ 8%。
三、 片剂生产工艺步骤
其中步骤七中制成片剂的步骤如下:
1、 将步骤六获得混合且灭菌后的药粉,上片剂生产线压片成型,其中, 生产片剂所说的辅料按重量比为麦芽糊精 25份、预胶化淀粉 25份和乳糖 27 份。 其中, 所述药粉及药用辅料用槽混机进行混合 50分钟后, 铺到不锈钢 盘中进行干燥, 干燥温度为 90 °C , 干燥后用粉碎机进行粉碎至 80目, 并通 过 80目整粒过筛。
2、 包薄膜衣用白膜浆的配制: 将羟丙基曱基纤维素(HPMC ) 1400份 和聚乙二醇( PEG ) 400份先后加入到 20000份 60 °C纯化水中, 边加边搅拌, 充分溶胀后再加入 20000份 95 %的乙醇配制得到包薄膜衣的白膜浆, 此过 程在包衣前 24 'J、时制备, 包衣前加入 2份钛白粉和 1 000份滑石粉, 搅拌 均匀后过胶体磨;
3、 包薄膜衣用色膜浆的配制: 称取纯化水 10500份, 将搅拌器伸入液 面下 2/3处, 启动搅拌器, 使液面形成漩涡, 将红色粉末的包衣剂 (GMI ) 2000份以平稳的速度不断撒在漩涡液面上, 再持续搅拌 45分钟至包衣剂完 全溶散配制得包薄膜衣的色膜浆;
4、 将压制后的基片放入高效包衣机内, 按常规制剂工艺启动包衣设备 各系统, 调整喷速、 进风量、 进风温度、 锅速、 排风量等参数, 将配制好的 白膜浆喷向片床, 经 2 ~ 3 小时后, 使片面光滑细腻; 再将配制好的色膜浆 喷向片床, 经 2 ~ 3小时后, 使片面细腻, 色泽均匀。
以上共计十种物料和三种辅料, 根据药物及辅料活性特点, 经过制粉、 水提和混合等制药工艺处理,每粒片剂净重 500毫克,并保持含水率 4 ~ 8%。
本发明中所采用的各组分原料药均可参见 《中华人民共和国药典》 ( 2010年版)和国内各省、 市、 区卫生、 药品食品监督管理等有关部门制定 的中药材、 药用辅料质量鉴定标准记载。
本发明的处方中十种药材原料的药典记载及药理性研究如下:
(一 )黄芩:
1、 中医药典籍描述:
《本草经疏》 中记载: 黄芩, 其性清肃, 所以除邪: 味苦所以燥湿; 阴
寒所以胜热, 故主诸热。
2、 对黄芩的现代药理学研究:
在第 10届国际艾滋病大会上, 日本学者报告中药成分 Baiicalien (黄苓 甙元)对抑制 HIV有良好作用。 黄苓甙元是黄芩的主要活性成分。 (资料来 源: 《山东中医杂志》 1995年 07期 )
(二)槐花:
1、 中医药典籍描述:
《本草正》 中记载: 槐花, 凉大肠, 杀疳虫。 治痈疽疮毒, 阴疮湿痒, 痔漏, 解杨梅恶疮, 下疳伏毒。
2、 对槐花的现代药理学研究:
研究槐花提取化合物 K3的体外抗 HIV-1活性, 并对其抗 HIV-1机制进 行初步探讨。
方法: 采用 MTT比色法检测化合物对各种细胞的毒性。 用合胞体形成 计数法, p24抗原捕获 ELISA法及 RT-PCR等多种方法研究化合物体外抗 HIV-1活性。
结论: 槐花提取化合物 K3体外有较好的抗 HIV-1活性, 能够抑制病毒 实验株 ( HIV-1IIIB ), 耐药株(HIV-1 74v )和临床分离株(HIV-1KM018 ) 等多种病毒株的复制,且其作用机制是多靶点的,不仅可以抑制病毒的进入, 还可以抑制 HIV-1逆转录酶活性。 (资料来源: 《槐花提取化合物 K3体外抗 HIV-1活性的研究》 中国科学院昆明动物研究所分子免疫药理学实验室, 云 南昆明 650223 中国科学院研究生院, 北京 100039 )
(三)黄芪:
1、 中医药典籍描述:
《本草汇言》 中记载: 黄芪, 补肺健脾, 卫实敛汗, 驱风运毒之药也。
2、 对黄芪的现代药理学研究
经收集 62 例艾滋病患者分为黄芪联合 HAART 治疗组 30 例和常规 HAART治疗组 32例, 各治疗 24周, 观察两组患者在治疗前及治疗后第 1、 3、 6个月时外周血中 CD4+T淋巴细胞的动态变化。
结果: 经 1、 3、 6个月治疗后两组 CD + 4T淋巴细胞均有不同程度提高,
与治疗前比较, 差异有统计学意义(P〈0.05 )。 两组间比较, 经 3、 6 个月 治疗后黄芪联合 HAART治疗 CD4+T淋巴细胞明显高于常规 HAART治疗 组, 差异有统计学意义(P〈0.05 )。
结论: 较单纯 HARRT治疗而言, 黄芪联合 HAART治疗能更有效提高 CD4+T淋巴细胞数量, 增强艾滋病患者免疫力。 (资料来源: 《中国热带资 料来源医学》 2011年第 11卷第 11期 1393-1393页)。
(四)、 黄精
1、 中医药典籍描述:
《本经逢原》 中记载: 黄精, 宽中益气, 使五藏调和, 肌肉充盛, 骨髓 强坚, 皆是补阴之功。
2、 对黄精的现代药理学研究
正黄精凝集素 ( Polygonatum cyrtonema Hua. Lectin )是从我国传统中草 药百合科植物黄精中纯化的一种多功能的甘露糖 /唾液酸结合凝集素,除血细 胞凝集活性、 促淋巴细胞有丝分裂活性外, 黄精凝集素的抗人类单纯疱疹病 毒活性以及抗乙型肝炎病毒活性显示其特殊的生物学活性;研究还发现黄精 凝集素能有效防止人类免疫缺陷病毒(HIV-1/2 )对正常细胞的感染。 (资料 来源: 《第十次中国生物物理学术大会论文摘要集》 2006年)
(五)、 熟地黄
1、 中医药典籍描述:
《本草纲目》 中记载: 熟地黄, 可填骨髓, 长肌肉, 生精血, 补五脏、 内伤不足, 通血脉, 利耳目, 黑须发, 男子五劳七伤, 女子伤中胞漏, 经候 不调, 胎产百病。
2、 对熟地黄的现代药理学研究:
采用环磷酰胺造模法制作免疫抑制小鼠模型, 进而观察怀地黄多糖对其 腹腔巨噬细胞吞噬功能、溶血素形成、溶血空斑形成、淋巴细胞转化的影响。
结果: 怀地黄多糖大小剂量均可使吞噬百分率、 吞噬指数显著升高; 可 显著促进溶血素和溶血空斑形成, 促进淋巴细胞的转化。
结论: 怀地黄多糖对低下的免疫功能有显著的兴奋作用。 (资料来源: 《中国中医药科技》 2002年 03期 《怀地黄多糖免疫兴奋作用的实验研究》)
(六)、 甘草
1、 中医药典籍描述:
《本草汇言》 中记载: 甘草, 和中益气, 补虚解毒之药也。 健脾胃, 固 中气之虚羸, 协阴阳, 和不调之营卫。 故治劳损内伤, 脾气虚弱, 元阳不足, 肺气衰虚, 其甘温平补, 效与参、 芪并也。
2、 对甘草的现代药理学研究 :
曰本 tohoku大学等研究机构的 14位研究者发现甘草的一种主要成份甘 草甜素 ( glycyrrhizine ), 能够防止艾滋病的发展。 他们于 86年 8月开始临 床研究甘草甜素对 11名艾滋病患者的药效, 甘草能有效地抗艾滋病毒。 (资 料来源: 《黑龙江中医药》 1988年 01期 《甘草能有效地抗艾滋病毒》)
(七)、 连翘
1、 中医药典籍描述:
《神农本草经》中记载: 主寒热, 鼠痿, 瘰疬, 痈肿恶疮, 瘿瘤, 结热。
2、 对连翘的现代药理学研究 :
连翘是一种常用的清热中药, 对合胞体病毒、 单纯疱疹病毒、 流感病毒 等多种病毒具有抑制作用。 (资料来源: 《中国医药导报》 2010年 02期 《连 翘抗病毒的研究进展》)
(八)、 冬虫夏草
1、 中医药典籍描述:
《本草正义》 中记载: 冬虫夏草, 始见于吴氏《本草从新》, 称其甘平, 保肺、 益肾、 补精髓, 止血化痰, 已劳嗽。
2、 对冬虫夏草的现代药理学研究 :
虫草不但具有扩张支气管、 调节心跳、 镇静催眠、 雄激素样作用, 而且 具有抗癌、 降血糖、 抗炎免疫调节作用等。 特别是近年来, 虫草的抗炎免疫 调节作用成为人们研究的热点,许多专家学者对虫草的抗炎免疫调节作用进 行了深入研究, 发现虫草具有增强单核-巨噬细胞吞噬功能, 刺激 T、 Β淋巴 细胞增殖, 增强 ConA、 PHA诱导的淋巴细胞增殖效应, 拮抗强的松等免疫 抑制剂的作用等, 并能对许多细胞因子产生影响。 (资料来源: 《安徽医药》 2004年第 3期 4页 163-166页 《冬虫夏草抗炎免疫调节作用的研究进展》)
(九)、 当归
1、 中医药典籍描述:
《本草正》 中记载: 当归, 其味甘而重, 故专能补血, 其气轻而辛, 故 又能行血, 补中有动, 行中有补, 诚血中之气药, 亦血中之圣药也。 大约佐 之以补则补, 故能养营养血, 补气生精, 安五脏, 强形体, 益神志, 凡有形 虚损之病, 无所不宜。
2、 对当归的现代药理学研究 :
当归多糖( AP )是当归中的主要成分之一, 近年来国内外对当归多糖的 成分研究和药理学研究有了新的进展, 发现其对机体免疫系统、 造血系统有 明显作用。 其对巨噬细胞(ΜΦ )有重要的防御功能, 它具有趋化性定向运 动、 吞噬和清除异物及衰老死亡细胞的功能, 分泌多种生物活性物质及参与 调节机体免疫应答。 当归可促进巨噬细胞分泌细胞因子, 增强免疫功能。 据 王瑾等报道: 当归多糖( AP )与瘤苗联用能显著增强荷瘤鼠的巨噬细胞介导 细胞毒作用, 提高了瘤苗的抗瘤效果。 AP 能增加小鼠血液钙的含量, 从而 补充机体对钙的需要, 保护免疫细胞, 增强巨噬细胞的吞噬功能。 AP 能增 强白介素 -2 ( IL-2 )、 白介素 -4 ( IL-4 )、 白介素 -6 ( IL-6 )和 γ干扰素( INF-γ ) 的表达, 其过程是首先激活涉及非特异性免疫作用的巨噬细胞和 ΝΚ细胞, 然后是 Τ辅助细胞, 增加抗体数量, 进而协同增强免疫功能。 (资料来源: 《四川畜牧兽医》 2005年第 03期《当归多糖对免疫系统作用的研究》)。
(十)、 柠檬酸
柠檬酸的药理作用:
柠檬酸又称枸橼酸纳, 枸橼酸根可与血中钙离子形成难解离的络合物, 钙离子是凝血过程中所需的物质之一, 血液中由于钙离子的减少, 而使血液 凝固受阻。 由于柠檬酸呈弱碱性, 在适度使用时可调节人体内环境酸碱度, 同时从理论上可在一定程度范围内抑制血细胞合胞体的形成。
本发明处方制剂的君臣佐使配伍原则如下:
君药: 黄芩、 黄芪(以清热解毒和扶正补气齐驱并驾)。
臣药: 槐花、 连翘、 黄精(辅佐君药)。
佐药: 熟地黄、 冬虫夏草、 甘草 (兼补气血并调和药性)。
使药: 当归 (由于艾滋病是 HIV-1感染表达 CD4蛋白的血细胞, 故将 药力引入血分)。
柠檬酸不是中药而作为辅助调节剂使用, 可配合当归活血(抗凝聚、 抑 制被感染血细胞合胞体形成而减少 CD4细胞凋亡)。 各味药材的用量也是根 据君臣佐使原则进行配伍。
根据现代药理学对上述药物的分析结果, 按照对艾滋病的治疗原则, 以 本发明制备的各类制剂的用药原则就是着重于抑制 HIV-1 和提升患者 CD4 细胞。
本发明的有益效果为:
1、本发明在中医理论的指导下,其是通过清热解毒(抗微生物病原体)、 扶正祛邪(增强人体免疫机能)相结合的原则来治疗艾滋病, 同时借鉴了现 代药理学研究的成果, 筛选出符合本发明治则的中药, 制出具有明显治疗效 果的中药制剂产品。 其组方原则为: 清热解毒类药材: 黄芩、 连翘、 槐花; 扶正类药材: 黄芪、 黄精、 熟地黄、 当归、 冬虫夏草、 甘草。
2、 本发明的原料容易取得, 服用方便、 成本低, 未见明显毒副作用, 安全性高。 在临床应用中疗效明显, 应用推广价值高, 对于改善艾滋病人临 床症状, 提高病人的生存生活质量效果显著。
以本发明制备的胶嚢剂来观察治疗艾滋病的临床疗效
依据本发明所制成的制剂,经反复跟踪了解,该制剂以中医处方药形式, 2002年以来在云南、河南等民间广泛用于艾滋病患者志愿者人体,显示了诸 多积极的药效。 经改进后改用胶嚢剂: 艾滋病患者和艾滋病病毒感染者患者 每天服用 12粒, 能够明显改善症状, 改善肝功能, 无西药抗病毒药物的毒 副反应。 服用后, 生活质量有所改善, 精神食欲好转, 生存质量明显提高, 生存期延长, 并逐渐恢复正常的生活和工作能力。
本发明采用胶嚢制剂治疗艾滋病和艾滋病毒感染者的初步临床试验资 料:
从 2004年以来, 以本发明处方胶嚢剂给药形式, 对河南省南部驻马店 市、 周口市艾滋病疫情较严重的上蔡、 西华等县的农村地区, 陆续对 238名
因献血感染 HIV-1的艾滋病患者和病毒感染者进行治疗。
病人入选的基本条件:
第一、被当地疾病预防控制中心确认为 HIV抗体阳性的艾滋病患者(感 染者); 第二、 外周血 CD4细胞等于或低于 400个 /ml、 第三、 在服药期间停 止抗逆转录酶西药治疗和其它抗病毒药物治疗、 提高免疫机能药物治疗。
冶疗方式和评判标准:
每名患者的治疗时间为 12个月, 每日服用本发明胶嚢 12粒, 治疗一年 后采用患者治疗前后的 CD4和患者症状改善情况为自身对照数据为疗效指 标。 并按国家中医药管理局《五省中医药治疗艾滋病项目临床技术方案》为 疗效评判标准;对抗 HIV-1的病毒载量由于资金和条件所限而暂未列入本次 治疗观察范畴。
安全性情况: 238例患者(感染者):
a、 服药 12个月结束时, 除中途因机会性感染并发症死亡 7名后的 231 名例患者 (感染者), 肝肾功能指标均无恶化情况, 其中有 156名患者(感 染者)谷丙转氨酶还有不同程度下降。 231例患者(感染者)服药前谷丙转 氨酶平均值由 57.6下降至 36.8; 尿酸、肌酐、尿素氮平均指标也有一定程度 下降。
b、 服药一年后治疗有效性统计: 238例患者(感染者)通过 12个月的 治疗后前后, 有 196名患者(感染者) 的 CD4淋巴细胞较治疗前明显上升, 平均上升值为 36.28%; 死亡 Ί名、稳定或无效( CD4下降或上升值低于 30% 均视为无效) 35名; 238名患者(感染者) CD4自身前后对照的医学统计学 结果为 PO.01 ; 高烧、腹泻和消瘦的症状改善率 175名。 总体有效率 82.3%。 大部分患者恢复了生活、 劳动生产能力。
c、 艾滋病是被 HIV-1感染所致, 由于艾滋病毒的破坏, 使 CD4T淋巴 细胞受到破坏或诱发 CD4细胞群体凋亡, 使患者 CD4细胞逐渐下降, 因此 只有抑制了病毒, CD4细胞才可能得到保存和回升,但由于本次治疗未将抗 病毒指标列入观察系, 因此对本发明处方胶嚢剂的抗 HIV 药效还无直接证 据, 为此, 目前已将本发明处方药送德国有关病毒实验室进行抑制 HIV-1活 性、 膜融合等多项与抗病毒有关的试验, 目前试验正在进行中。
以上所揭露的仅为本发明较佳实施例而已, 当然不能以此来限定本发明 之权利范围, 因此等同变化, 仍属本发明所涵盖的范围。
Claims
1、 一种治疗艾滋病的中药制剂, 其特征在于, 是由下述重量配比的原 料制成的制剂:
黄芩 60 ~ 90份, 槐花 60 ~ 90份, 黄芪 120 ~ 250份, 当归 120份 -250 份, 黄精 120 ~ 250份, 熟地黄 90 ~ 150份, 甘草 20 ~ 55份, 连翘 120 ~ 250 份, 冬虫夏草 25 ~ 60份, 柠檬酸 60 ~ 90份。
2、 如权利要求 1 所述的治疗艾滋病的中药制剂, 其特征在于, 所述中 药制剂组分是各配比原料中提取的所有化合物、生物活性成分及各类分子簇 及衍生物、 全化学合成物中至少一种。
3、 如权利要求 1或 2所述的一种治疗艾滋病的中药制剂的制备方法, 其特征在, 包括:
按组分重量配比分别取冬虫夏草、 槐花、 连翘、 柠檬酸四味药料, 经粉 碎至 80目后过 80目筛, 对过 80目筛后的药粉进行灭菌处理, 备用;
按组份重量配比分别取黄芪、 黄精、 甘草、 黄芩、 当归和熟地黄, 加水 煎煮二次: 第一次按原药材的 10倍重量加水煎煮 2小时, 第二次按原药材 的 8倍量加水煎煮 2 小时, 滤过并合并滤液, 将滤液干燥浓缩成相对密度 1.2 ~ 1.25的浸膏, 经粉碎至 80目后过 80目筛获得浸膏粉体, 备用;
将上述灭菌后的药粉、 浸膏粉体及药用辅料采用槽混机进行混合 50分 钟后, 再对其进行整粒过 80 目筛, 对过筛混合后的药粉行灭菌处理, 所用 的药用辅料为麦芽糊精、 预胶化淀粉和乳糖中至少一种;
将上述混合且灭菌后的药粉制备成胶嚢、 片剂、 糖浆剂、 口服液或颗粒 散剂中的任一种。
4、 如权利要求 3所述的制备方法, 其特征在于, 在按重量配比取黄芪、 当归、 黄精、 甘草、 黄芩、 熟地黄、 槐花、 连翘、 冬虫夏草之后, 进一步包 括:
对所述药材进行去尘处理的步骤, 包括:
用电动振筛进行振动 10分钟, 经振动后将混杂在药材中的粉尘除去, 或者
用饮用流动水清洗至少二次。
5、 如权利要求 3所述的一种治疗艾滋病的中药制剂的制备方法, 其特 征在于, 对冬虫夏草、 槐花、 连翘、 柠檬酸四味药料粉碎之前进一步包括: 将槐花、 连翘、冬虫夏草药材用离心机进行脱水后,控制温度在 60±5°C 进行干燥, 干燥至含水率 3 ~ 8%。
6、 如权利要求 4所述的制备方法, 其特征在于, 所述灭菌处理具体为: 用钴 60灭菌方法、 紫外线灭菌方法、 臭氧灭菌方法中至少一种进行灭 菌处理。
7、 如权利要求 6所述的制备方法, 其特征在于, 所述将滤液干燥浓缩 成相对密度 1.2 ~ 1.25的浸膏的步骤具体为:
采用干燥温度为 30 ~ 50°C的真空喷雾干燥方式对滤液进行干燥处理;或 者
采用干燥温度为 90±5 °C的蒸汽干燥方式对滤液进行干燥处理。
8、 如权利要求 3-7任一项所述的制备方法, 其特征在于, 将上述混合 且灭菌后的药粉制备成片剂的步骤具体为:
将羟丙基曱基纤维素 HPMC1400份和聚乙二醇 PEG400份先后加入到 20000份 60 °C纯化水中, 边加边搅拌, 充分溶胀后再加入 20000份 95 %的 乙醇配制得到包薄膜衣的白膜浆, 此过程在包衣前 24小时制备, 包衣前加 入 2 000份钛白粉和 1000份滑石粉, 搅拌均勾后过胶体磨;
称取纯化水 10500份, 将搅拌器伸入液面下 2/3处, 启动搅拌器, 使液 面形成漩涡, 将红色粉末的包衣剂 GMI 2 000份以平稳的速度不断撒在漩涡 液面上, 再持续搅拌 45分钟至包衣剂完全溶散配制得包薄膜衣的色膜浆; 将所述混合且灭菌后的药粉压制成基片, 将所述基片放入高效包衣机 内, 采用常规的制剂工艺, 将配制好的白膜浆喷向片床, 经 2 ~ 3 小时后, 再将配制好的色膜浆喷向片床, 经 2 ~ 3小时后, 片面光滑细腻即得。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210306769.7 | 2012-08-27 | ||
CN2012103067697A CN102805810B (zh) | 2012-08-27 | 2012-08-27 | 一种治疗艾滋病的中药制剂及相应的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014032541A1 true WO2014032541A1 (zh) | 2014-03-06 |
Family
ID=47229794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/082076 WO2014032541A1 (zh) | 2012-08-27 | 2013-08-22 | 一种治疗艾滋病的中药制剂及相应的制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102805810B (zh) |
WO (1) | WO2014032541A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102805810B (zh) * | 2012-08-27 | 2013-10-02 | 张�林 | 一种治疗艾滋病的中药制剂及相应的制备方法 |
CN104800502B (zh) * | 2015-04-10 | 2018-05-01 | 刘玉莲 | 一种控制hiv病毒口服液及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102210837A (zh) * | 2010-04-09 | 2011-10-12 | 肖嘉惠 | 治疗艾滋病的药物 |
CN102805810A (zh) * | 2012-08-27 | 2012-12-05 | 张�林 | 一种治疗艾滋病的中药制剂及相应的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1145240A (zh) * | 1996-05-31 | 1997-03-19 | 黄英秀 | 一种抗艾滋病毒及抗癌的药物组合物 |
CN1198348A (zh) * | 1998-05-25 | 1998-11-11 | 蔡又明 | 治疗艾滋病的a、b配方 |
-
2012
- 2012-08-27 CN CN2012103067697A patent/CN102805810B/zh active Active
-
2013
- 2013-08-22 WO PCT/CN2013/082076 patent/WO2014032541A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102210837A (zh) * | 2010-04-09 | 2011-10-12 | 肖嘉惠 | 治疗艾滋病的药物 |
CN102805810A (zh) * | 2012-08-27 | 2012-12-05 | 张�林 | 一种治疗艾滋病的中药制剂及相应的制备方法 |
Non-Patent Citations (4)
Title |
---|
DING, DONGXING: "Retrospection of research on plant-based medicine against AIDS", JOURNAL OF ANHUI HEALTH VOCATIONAL & TECHNICAL COLLEGE, vol. 2, no. 6, 31 December 2003 (2003-12-31) * |
GAO, WEI ET AL.: "Aizibing zhiliao yaowu gaikuang", JIANGSU PHARMACEUTICAL AND CLINICAL RESEARCH, vol. 11, no. 5, 31 December 2003 (2003-12-31) * |
MA, BOYAN ET AL.: "Zhongyao ji zhongyao fufang zhiji kang renlei mianyi quexian bingdu de yanjiu jinzhan", INFORMATION ON TRADITIONAL CHINESE MEDICINE, vol. 24, no. 2, 31 December 2007 (2007-12-31), pages 17 - 20 * |
WANG, XIANBO ET AL.: "Zhongyiyao zhiliao aizibing de yanjiu jinzhan", BEIJIN JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 26, no. 1, 31 January 2007 (2007-01-31), pages 7 - 9 * |
Also Published As
Publication number | Publication date |
---|---|
CN102805810B (zh) | 2013-10-02 |
CN102805810A (zh) | 2012-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI792162B (zh) | 一種具有清肺排毒功能的中藥複方及其應用 | |
JP2004161732A (ja) | Hiv/エイズ患者の処置のための生薬医薬組成物 | |
WO2021208335A1 (zh) | 解毒化湿利咽中药组合物及其应用 | |
CN105998599A (zh) | 一种治疗病毒性呼吸道感染的中药组合物及其制备方法 | |
WO2014032541A1 (zh) | 一种治疗艾滋病的中药制剂及相应的制备方法 | |
CN1290544C (zh) | 一种主治急慢性肝炎的药物 | |
CN113577187B (zh) | 一种治疗流行性感冒的中药组合物、中药提取物及其制备方法和应用 | |
CN116139237A (zh) | 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用 | |
CN109528868A (zh) | 一种中药组合物在制备治疗口舌生疮,痈肿疔疮的药物中的应用 | |
CN101695562B (zh) | 一种治疗病毒性肝炎的中药组合物及其制备方法 | |
WO2006015556A1 (fr) | A combinaison antivirale et fabrication de celle-ci | |
CN102133336B (zh) | 一种中药组合物及其制备方法和应用 | |
CN113616764A (zh) | 抗病毒中药组合物及其应用 | |
CN103585291B (zh) | 一种展毛翠雀提取物在制备治疗艾滋病药物中的应用 | |
CN103585212B (zh) | 阿莫尼亚脂提取物在制备治疗艾滋病药物中的应用 | |
CN1256976C (zh) | 一种抗癌中药组合物及其制备方法 | |
CN107802681B (zh) | 一种改善hiv感染者临床症状体征的组合物 | |
CN103585259B (zh) | 一种白花油麻藤提取物在制备治疗艾滋病药物中的应用 | |
CN103585222B (zh) | 一种褐毛橐吾提取物在制备治疗艾滋病药物中的应用 | |
CN104771558A (zh) | 治疗肾炎的中药组合物及制备方法 | |
CN104510742A (zh) | 一种治疗艾滋病的药物组合物 | |
CN104510740A (zh) | 一种治疗艾滋病的药物组合物 | |
CN103585239B (zh) | 一种齿缘草提取物的制备方法及其应用 | |
CN103585219B (zh) | 一种阿尔泰狗娃花提取物在制备治疗艾滋病药物中的应用 | |
CN103585188B (zh) | 壁衣提取物在制备治疗艾滋病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13832326 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13832326 Country of ref document: EP Kind code of ref document: A1 |